Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Chelsea Therapeutics International (NASDAQ:CHTP), TESARO Inc (NASDAQ:TSRO), Vanda Pharmaceuticals (NASDAQ:VNDA)

Geron Corp. (NASDAQ:GERN)‘s stock had its “positive” rating reaffirmed by equities researchers at Wells Fargo & Co. in a research report issued on Thursday, AnalystRatings.NETreports. Geron Corporation (NASDAQ:GERN) stock performance was 5.62% in last session and finished the day at $1.78. Traded volume was 16,397,352 million shares in the last session and the average volume of the stock remained 5.30 million shares. The beta of … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Chelsea Therapeutics International (NASDAQ:CHTP), TESARO Inc (NASDAQ:TSRO), Vanda Pharmaceuticals (NASDAQ:VNDA)

Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Geron Corporation (NASDAQ:GERN)  got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The … Continue reading Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)

Geron Corporation (NASDAQ:GERN) said the US Food and Drug Administration ordered a halt to trials of a cancer drug over concerns about potential liver damage. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of … Continue reading Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)

Moving Stocks: Geron Corporation (NASDAQ:GERN), Alcatel Lucent SA (ADR) (NYSE:ALU), CenterState Banks, Inc. (NASDAQ:CSFL), Highpower International, Inc. (NASDAQ:HPJ), Ensco plc (NYSE:ESV)

Geron Corp (NASDAQ:GERN) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $240 thousand. The company also announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on Geron’s investigational new drug (IND) application for imetelstat. In addition, the FDA stated that Geron’s … Continue reading Moving Stocks: Geron Corporation (NASDAQ:GERN), Alcatel Lucent SA (ADR) (NYSE:ALU), CenterState Banks, Inc. (NASDAQ:CSFL), Highpower International, Inc. (NASDAQ:HPJ), Ensco plc (NYSE:ESV)

Shining on Major News : ProQR Therapeutics (NASDAQ:PRQR), Array BioPharma (NASDAQ:ARRY), Brooks Automation (NASDAQ:BRKS), Taubman Centers, Inc. (NYSE:TCO),GERN

ProQR Therapeutics N.V. (NASDAQ:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 … Continue reading Shining on Major News : ProQR Therapeutics (NASDAQ:PRQR), Array BioPharma (NASDAQ:ARRY), Brooks Automation (NASDAQ:BRKS), Taubman Centers, Inc. (NYSE:TCO),GERN